Ranibizumab

Showing results 51 - 56 of 56

Sorted by most recent

TitleAuthorDate

Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy

Manabu Miyata, Sotaro Ooto, Kenji Yamashiro, Hiroshi Tamura, Masayuki Hata, Naoko Ueda-Arakawa, Munemitsu Yoshikawa, Shogo Numa, Akitaka Tsujikawa

6 June 2018

Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study

Charles C Wykoff, William C Ou, Rahul N Khurana, David M Brown, W Lloyd Clark, David S Boyer

13 April 2018

Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy

Shinichi Sakamoto, Hidenori Takahashi, Xue Tan, Yuji Inoue, Yoko Nomura, Yusuke Arai, Yujiro Fujino, Hidetoshi Kawashima, Yasuo Yanagi

22 March 2018

Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data

Aaron Y Lee, Thomas Butt, Emily Chew, Elvira Agron, Traci E Clemons, Catherine A Egan, Cecilia S Lee, Adnan Tufail

22 March 2018

Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial

Charles C Wykoff, William C Ou, Daniel E Croft, John F Payne, David M Brown, W Lloyd Clark, Nizar Saleh Abdelfattah, SriniVas R Sadda

22 March 2018

Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema

Bianca S Gerendas, Sonja Prager, Gabor Deak, Christian Simader, Jan Lammer, Sebastian M Waldstein, Tadhg Guerin, Michael Kundi, Ursula Margarethe Schmidt-Erfurth

20 January 2018

Prev 1 2 3 4 56